Lymphedema, Lymphedema, Breast Cancer
Conditions
Brief summary
Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema. Additionally, to determine if this procedure improves objective outcomes of lymphedema and patient quality of life
Interventions
PROCEDUREaxillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)
lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
PROCEDUREAxillary lymphadenetomy alone
oncologic axillary lymphadenectomy
PROCEDUREaxillary lymphadenectomy with soft tissue reinforcement
axillary lymphadenectomy with soft tissue reinforcement(STR)
Sponsors
Stanford University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Ages 18 to 75 years (inclusive) * Patients undergoing unilateral or bilateral breast cancer related axillary lymphadenectomy * Free of distant metastasis in preoperative screening * Histology results of axillary lymph nodes could be either Negative or Positive * Patients who undergo preoperative chemotherapy can be included * Willingness and ability to provide written informed consent * Willingness and ability to comply with all study procedures
Exclusion criteria
* Primary lymphedema of the affected upper limb * Secondary lymphedema of the affected limb prior to the lymphadenectomy * Radiotherapy at the axilla before the study / surgery * Allergic reaction to porcine collagen or ICG * Receiving radiation therapy to the involved nodal basin in a period less than 4 weeks after the surgery * Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening * Other medical condition that could lead to limb edema, such as (but not limited to primary lymphedema or acute venous thrombosis * Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (e.g., pain, swelling, decreased range of motion) * Either of the following, at the time of baseline evaluation: ipsilateral:contralateral limb volume ratio\>1.1 or R0 bioimpedance ratio \> 1.106 when the nondominant limb is at risk, and 1.134 when the dominant limb is at risk. * Life expectancy \< 2 years for any reason * Pregnancy or nursing * Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening * Severe psychiatric disease * Significant or chronic renal insufficiency (defined as serum creatinine \> 2.5 mg/dL or an estimated glomerular filtration rate \[eGFR\] \< 30 mL/min at screening) or requires dialytic support * Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase (AST) levels \> 3 × upper limit of the normal range (ULN) and/or bilirubin level \> 2 × ULN at screening * Absolute neutrophil count \< 1500 mm3 at screening * Hemoglobin concentration \< 9 g/dL at screening * Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lymphatic flow pattern of whole limb | 2 yr | In the early lymphedema stages this exam allows to detect percutaneously the lymphatic vessels of the whole limb, up to about 1 cm in depth from the skin surface, by an infrared camera visualization system after intra-dermal injection of ICG in the hand. The change in the lymphatic pattern and reduction in the ICG velocity will be tested to find a correlation with other used diagnostic parameters like volume change and bioimpedance spectroscopy. |
| Limb Volume | 2 yr | Limb volume as measured by serial assessment |
| Skin thickness measurements | 2 yr | Skin thickness is changed by lymphedema |
| Bioiimpedance spectroscopy | 2 yr | Impedance of the skin changes with lymphedema |
| Quality of Life- Limb-Lymphedema-Specific Quality of Life (LYMQOL) | 2 yr | Questionnaire to determine patient reported quality of life. Measured by limb-lymphedema-specific quality of life (LYMQOL) tool. The LYMQOL is divided into four domains: Function, Appearance, Symptoms, and Mood, as well as yielding an overall quality-of-life score. Domain scores range from 0 to 4, with higher scores indicating greater impairment and worse quality of life. An additional overall quality of life score ranges from 0 to 10, with higher scores indicating better overall quality of life. |
Countries
United States
Contacts
CONTACTDung Nguyen, MD, PharmD
PRINCIPAL_INVESTIGATORDung Nguyen, MD, PharmD
Stanford University
Outcome results
None listed